Last €22.64 EUR
Change Today -0.265 / -1.16%
Volume 50.0
As of 4:15 AM 09/1/14 All times are local (Market data is delayed by at least 15 minutes).

eckert & ziegler strahlen un (EUZ) Snapshot

Open
€22.94
Previous Close
€22.90
Day High
€23.00
Day Low
€22.64
52 Week High
01/20/14 - €30.67
52 Week Low
08/13/14 - €21.00
Market Cap
119.8M
Average Volume 10 Days
2.0K
EPS TTM
€1.59
Shares Outstanding
5.3M
EX-Date
05/23/14
P/E TM
14.2x
Dividend
€0.60
Dividend Yield
2.65%
Current Stock Chart for ECKERT & ZIEGLER STRAHLEN UN (EUZ)

Related News

No related news articles were found.

eckert & ziegler strahlen un (EUZ) Related Businessweek News

No Related Businessweek News Found

eckert & ziegler strahlen un (EUZ) Details

Eckert & Ziegler Strahlen & Medizintechnik AG and its subsidiaries provide isotope technology for medical, scientific, and industrial use primarily in Europe. The company’s Radiation Therapy segment produces and distributes medical devices for brachytherapy, a form of radiotherapy that treats cancer by irradiation from a short distance. This segment offers seeds for the treatment of localised prostate cancer; high dose rate (HDR) afterloaders to treat gynaecological cancers and other tumour sites; applicators for intraluminal, interstitial, intracavitary, and intraoperative treatments, as well as surface mould treatments; and support software of HDR planning. The Radiation Therapy segment also provides products for temporary brachytherapy of eye cancers and radiotherapy accessories. This segment’s products and equipment are intended for use by oncologists, radio-therapists, urologists, ophthalmologists, and medical physicists. Its Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration, and environmental monitoring sources and solutions; and bulk radioisotopes for pharmaceutical, therapeutic, and industrial product manufacturers. This segment offers custom and one-off design and manufacturing services. The company’s Radiopharma segment operates in the field of molecular imaging and nuclear medicine supplying various radiopharmaceuticals, radiochemicals, and related equipment for the synthesis and radiochromatography of PET/SPECT tracers and other radioisotopes. This segment offers products in the categories of radiosynthesis technology, radiochromatography, and radionuclides. Its Environmental Services segment collects, measures, sorts, treats, and packs low level radioactive waste from hospitals, research institutes, and industry for its final disposal. Eckert & Ziegler Strahlen & Medizintechnik AG was founded in 1992 and is headquartered in Berlin, Germany.

Founded in 1992

eckert & ziegler strahlen un (EUZ) Top Compensated Officers

Chairman of The Executive Board, Chief Execut...
Total Annual Compensation: €512.0K
Head of Radiopharma Segment, Member of The Ex...
Total Annual Compensation: €292.0K
Head of Radiation Therapy Segment, Member of ...
Total Annual Compensation: €282.0K
Compensation as of Fiscal Year 2013.

eckert & ziegler strahlen un (EUZ) Key Developments

Eckert & Ziegler Strahlen & Medizintechnik AG Announces Board Changes

Eckert & Ziegler Strahlen & Medizintechnik AG announced that effective August 1, 2014, the lawyer Prof. Dr. Helmut Grothe took over as the successor of Dr. Fritz Oesterle, who resigned from the Supervisory Board effective July 31 due to other obligations that would not leave him enough time to look after the interests of the company in the future with the required amount of diligence. Prof. Dr. Grothe was elected to become the new member at the last Annual General Meeting in May.

Eckert & Ziegler Strahlen & Medizintechnik AG Reports Financial Results for the Second Quarter and First Half Year of 2014; Reaffirms Financial Forecast for the Year 2014

Eckert & Ziegler Strahlen & Medizintechnik AG reported financial results for the second quarter and first half year of 2014. The company increased sales by 8% year on year to EUR 31.2 million in the second quarter of 2014. Sales rose by EUR 6.6 million, or 12%, to EUR 61.9 million during the first half year of 2014. A total EUR 2.1 million of this amount was attributable to organic sales growth. Earnings before interest and taxes (EBIT) came to EUR 6.2 million in the first half year of 2014, equating to a drop of EUR 0.7 million, or 10%, year on year. This decrease was primarily the result of negative effects in the Radiation Therapy and Isotope Products segments. Earnings after taxes and minority interests fell by 18% to EUR 3.3 million, or EUR 0.62 per share due to the decline in EBIT. The Executive Board has reaffirmed its most recent forecast for the year 2014. Based on expectations of a disproportionate increase in profit in the Radiation Therapy segment, the targets for the year remain at sales of EUR 134 million and earnings after tax and minority interests of EUR 10.5 million, or EUR 2.00 per share.

Eckert & Ziegler Strahlen & Medizintechnik AG, Q2 2014 Earnings Call, Aug 05, 2014

Eckert & Ziegler Strahlen & Medizintechnik AG, Q2 2014 Earnings Call, Aug 05, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EUZ:GR €22.64 EUR -0.265

EUZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $25.98 USD -0.03
View Industry Companies
 

Industry Analysis

EUZ

Industry Average

Valuation EUZ Industry Range
No financial data is available for EUZ.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ECKERT & ZIEGLER STRAHLEN UN, please visit www.ezag.de. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.